Bone Marrow Morphologic Features in Polycythemia Vera With JAK2 Exon 12 Mutations

被引:20
|
作者
Lakey, Meredith A. [1 ]
Pardanani, Animesh [2 ]
Hoyer, James D. [1 ]
Nguyen, Phuong L. [1 ]
Lasho, Terra L. [2 ]
Tefferi, Ayalew [2 ]
Hanson, Curtis A. [1 ]
机构
[1] Mayo Clin, Coll Med, Div Hematopathol, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Div Hematol, Rochester, MN 55905 USA
关键词
Polycythemia vera; Myeloproliferative neoplasms; JAK2; Bone marrow; TYROSINE KINASE JAK2; ESSENTIAL THROMBOCYTHEMIA; MPL MUTATIONS; ERYTHROCYTOSIS; V617F; DISORDERS;
D O I
10.1309/AJCP3Z2AKUWRGTNM
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The diagnosis of polycythemia vera (PV) requires the integration of clinical and laboratory findings, bone marrow morphologic features, and JAK2 analysis. JAK2(V617F) (exon 14) mutation is found in 95% of PV cases. Functionally similar mutations in JAK2 exon 12 have also been described, but a thorough bone marrow study has not been done. We identified 7 PV cases with exon 12 mutations; all had hypercellular bone marrow with elythroid hyperplasia. Small, atypical megakagocytes predominated; atypical megakaryocyte lobation and abnormal chromatin distribution was identified in all cases. Rare clusters of megakagocytes could be found but were typically subtle. Because JAK2 exon 12-positive PV cases lack the classic myeloproliferative morphologic features, bone marrow samples from the patients may be difficult to classify as myeloproliferative neoplasms. Clinically suspected PV with low serum erythropoietin and absent JAK2(V617F), together with the bone marrow. findings of erythroid hyperplasia and subtle megakaryocytic atypia, should prompt an evaluation for an exon 12 mutation.
引用
收藏
页码:942 / 948
页数:7
相关论文
共 50 条
  • [31] The role of parathyroidectomy in JAK2 mutation negative polycythemia vera
    Afif N. Kulaylat
    Eric E. Jung
    Brian D. Saunders
    International Journal of Hematology, 2014, 100 : 615 - 618
  • [32] Presence of calreticulin mutations in JAK2-negative polycythemia vera
    Broseus, Julien
    Park, Ji-Hye
    Carillo, Serge
    Hermouet, Sylvie
    Girodon, Francois
    BLOOD, 2014, 124 (26) : 3964 - 3966
  • [33] Bone marrow renin-angiotensin system expression in polycythemia vera and essential Thrombocythemia depends on JAK2 mutational status
    Vrsalovic, Maruska Marusic
    Pejsa, Vlatko
    Veic, Taiana Stoos
    Kolonic, Slobodanka Ostojic
    Ajdukovic, Radmila
    Haris, Visnia
    Jaksic, Ozren
    Kusec, Raiko
    CANCER BIOLOGY & THERAPY, 2007, 6 (09) : 1434 - 1436
  • [34] JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera
    Zhang, Sujiang
    Qiu, Hongxia
    Fischer, Bruce S.
    Li, Weida
    Duan, Limin
    Sun, Xuemei
    Xu, Wei
    Li, Jianyong
    LEUKEMIA & LYMPHOMA, 2008, 49 (04) : 696 - 699
  • [35] A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
    Verstovsek, Srdan
    Courby, Stephane
    Griesshammer, Martin
    Mesa, Ruben A.
    Brachmann, Carrie Baker
    Kawashima, Jun
    Maltzman, Julia D.
    Shao, Lixin
    Xin, Yan
    Huang, Daniel
    Bajel, Ashish
    LEUKEMIA RESEARCH, 2017, 60 : 11 - 17
  • [36] Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation
    Suknuntha, Kran
    Geyer, Julia T.
    Patel, Keyur Pravinchandra
    Weinberg, Olga K.
    Rogers, Heesun J.
    Lake, Jonathan I.
    Lauridsen, Luke
    Patel, Jay L.
    Kluk, Michael J.
    Arber, Daniel A.
    Hsi, Eric D.
    Bagg, Adam
    Bueso-Ramos, Carlos
    Orazi, Attilio
    LEUKEMIA RESEARCH, 2023, 127
  • [37] Bone marrow findings in blast phase of polycythemia vera
    Lopez, Juliana E. Hidalgo
    Carballo-Zarate, Adrian
    Verstovsek, Srdan
    Wang, Sa A.
    Hu, Shimin
    Li, Shaoying
    Xu, Jie
    Zuo, Wenli
    Tang, Zhenya
    Yin, C. Cameron
    Medeiros, L. Jeffrey
    Bueso-Ramos, Carlos E.
    Tang, Guilin
    ANNALS OF HEMATOLOGY, 2018, 97 (03) : 425 - 434
  • [38] A Multiplexed Fragment Analysis-Based Assay for Detection of JAK2 Exon 12 Mutations
    Furtado, Larissa V.
    Weigelin, Helmut C.
    Elenitoba-Johnson, Kojo S. J.
    Betz, Bryan L.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 592 - 599
  • [39] Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2
    Bartels, S.
    Faisal, M.
    Buesche, G.
    Schlue, J.
    Kreipe, H.
    Lehmann, U.
    LEUKEMIA, 2018, 32 (02) : 556 - 558
  • [40] JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
    Tefferi, Ayalew
    Lavu, Sravanthi
    Mudireddy, Mythri
    Lasho, Terra L.
    Finke, Christy M.
    Gangat, Naseema
    Pardanani, Animesh
    Hanson, Curtis A.
    Mannarelli, Carmela
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (04) : E93 - E96